Related Experiment Videos
Genotoxic effects of metronidazole
G Elizondo1, M E Gonsebatt, A M Salazar
1Instituto de Investigaciones Biomédicas, UNAM, Ciudad Universitaria, México D.F., Mexico.
Mutation Research
|September 13, 1996
Summary
Metronidazole (MTZ) treatment increased chromosomal aberrations in human lymphocytes, despite prior negative in vivo studies. Individual responses varied, possibly due to metabolic differences in drug processing.
Area of Science:
- Pharmacology
- Genetics
- Toxicology
Background:
- Metronidazole (MTZ) is widely used for parasitic infections.
- Genotoxicity of MTZ is established in prokaryotes but debated in humans.
- Previous human in vivo studies reported negative results regarding MTZ genotoxicity.
Purpose of the Study:
- To evaluate chromosomal aberration frequencies in human lymphocytes after MTZ treatment.
- To investigate the relationship between MTZ plasma levels and aberration induction.
- To explore individual variability in MTZ response.
Main Methods:
- Peripheral blood lymphocyte cultures from 10 individuals were analyzed.
- Chromosomal aberration frequencies were assessed before and after MTZ treatment (1500 mg/day for 10 days).
- Metronidazole plasma concentrations were measured.
Main Results:
- A significant increase in chromatid and isochromatid breaks was observed post-treatment.
- No correlation was found between aberration frequencies and MTZ plasma levels.
- Significant individual variability in both aberration induction and MTZ levels was noted.
Conclusions:
- MTZ treatment can induce chromosomal aberrations in human lymphocytes.
- Individual metabolic differences, potentially involving cytochrome P450, may explain variable responses.
- Further research into MTZ's genotoxic potential and metabolic pathways is warranted.